59134-89-3

Usage

Uses

Used in Medicinal Chemistry:
8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE is used as a chemical scaffold for the design of new compounds with potential biological activities, facilitating the creation of pharmaceuticals with diverse therapeutic applications.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE is used as an antimicrobial agent for its ability to inhibit the growth of certain microorganisms, contributing to the development of new treatments for infectious diseases.
Used in Antimalarial Applications:
8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE is used as an antimalarial agent, showing promise in the inhibition of parasite growth, which is crucial for the development of new drugs to combat malaria.
Used in Drug Development:
In the pharmaceutical industry, 8-CHLORO[1,3]DIOXOLO[4,5-G]QUINOLINE is used as a starting point for the development of new drugs, targeting a range of diseases by leveraging its potential biological activities.

InChI:InChI=1/C10H6ClNO2/c11-7-1-2-12-8-4-10-9(3-6(7)8)13-5-14-10/h1-4H,5H2

Upstream product

• 154504-43-5 6,7-methylenedioxy-4-quinolone 
• 26893-27-6 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylic acid 
• 74-97-5 chlorobromomethane 
• 593-71-5 Chloroiodomethane 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 14205-65-3 ethyl 8-hydroxy-1,3-dioxolo[4,5-g]quinoline-7-carboxylate 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 
• 17394-77-3 diethyl [[3,4-(methylenedioxy)phenylamino]methylene]malonate 
• 28657-75-2 2-amino-4,5-methylenedioxy-acetophenone 
• 35478-79-6 4-hydroxy-6,7-methylenedioxyquinoline 

Downstream Products

• 847573-77-7 4-[[2-(4-benzylpiperazin-1-yl)ethyl]amino]-6,7-methylenedioxyquinoline 
• 500214-47-1 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(N,N-dimethylamino)-1-methylethyl]-2-iodo-4,5-dimethoxybenzamide 
• 500214-46-0 N-(6,7-methylenedioxyquinolin-4-yl)-N-(2-N,N-dimethylaminoethyl)-2-iodo-4,5-dimethoxybenzamide 
• 500214-48-2 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(tetrahydrofuran-2-yl)]-2-iodo-4,5-dimethoxybenzamide 
• 528879-63-2 N-(6,7-methylenedioxyquinolin-4-yl)-N-(butyl)-2-iodo-4,5-dimethoxybenzamide 
• 529488-48-0 N-(6,7-methylenedioxyquinolin-4-yl)-N-[3-(N,N-dimethylamino)propyl]-2-iodo-4,5-dimethoxybenzamide 
• 586415-76-1 8,9-dimethoxy-2,3-methylenedioxy-5-[2,2-dimethyl[1,3]dioxolan-4-yl-methyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one 
• 529488-46-8 N-(6,7-methylenedioxyquinolin-4-yl)-N-[(2-pyrrolidin-1-yl)ethyl]-2-iodo-4,5-dimethoxybenzamide 
• 529488-53-7 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(t-butyldimethylsilanyloxy)ethyl]-2-iodo-4,5-dimethoxybenzamide 
• 529488-47-9 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(4-methyl-1-piperazinyl)ethyl]-2-iodo-4,5-dimethoxybenzamide 
• 529488-55-9 N-(6,7-methylenedioxyquinolin-4-yl)-N-[1-[(t-butyldimethylsilanyloxy)methyl]-N-2-dimethylaminoethyl]-2-iodo-4,5-dimethoxybenzamide 
• 529488-54-8 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(2-(t-butyldimethylsilanyloxy)ethoxy)ethyl]-2-iodo-4,5-dimethoxybenzamide 
• 1489230-70-7 C₃₃H₄₀BrN₅O₉ 
• 1489230-67-2 C₃₂H₃₈BrN₅O₉ 

Relevant academic research and scientific papers

INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND USE OF SAME IN MEDICINE

The present invention relates to a compound represented by formula I, a pharmaceutical composition containing the compound of formula I, a method for inhibiting indoleamine 2,3-dioxygenase, and its use in medicine.

TAM family kinase and/or CSF1R kinase inhibitor and application thereof

The invention provides a novel inhibitor compound shown in a general formula (I). The compound has good kinase inhibition activity and can be used for preventing and/or treating diseases mediated by abnormal expression of TAM family kinase and/or a ligand thereof. The compound can target CSF1R kinase and can be used for preventing and/or treating diseases mediated by abnormal expression of a TAM family kinase receptor and/or a CSF1R kinase receptor and/or ligands thereof.

METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES

The invention provides methods and pharmaceutical compositions for treating certain hematological cancers

METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES

The invention provides methods and pharmaceutical compositions for treating pancreatic cancer or gastric cancer or a metastasis thereof.

5-(2-Aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: Variation of N-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance

5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c, h]-[1,6]naphthyridin-6-one (ARC-111) has potent TOP1-targeting activity and pronounced antitumor activity. Several analogues of ARC-111 were synthesized with NH2, N-alkyl, N,N-dialkyl, pyrrolidinyl, piperidinyl, and piperazinyl substituents at the 2-position of the 5-ethyl group. The relative TOP1-targeting activity and cytotoxicity of these structural analogues were assessed in RPMI8402 and P388 tumor cells and their camptothecin-resistant variants CPT-K5 and P388/CPT45, respectively. Potent TOP1-targeting activity was retained within a series of mono N-alkyl analogues that included NHCH 2CH3, NHCH(CH3)2, and NHC(CH 3)3. TOP1-targeting activity was diminished by the presence of a N-benzyl moiety. In a comparison of a series of N-alkyl-N-isopropyl analogues, activity decreased in the order CH3 > CH2CH3 > CH-(CH3)2. Cytotoxicity in RPMI8402 and P388 did correlate with TOP1-targeting activity. Cytotoxic activity was also determined in KB3-1 cells and its variants KB/V-1 and KBH5.0. As KB/V-1 cells overexpress MDR1 and KBH5.0 cells overexpress BCRP, decreased cytotoxicity in these cell lines relative to the parent cell line is indicative of compounds that are substrates for these efflux transporters. In view of their diminished cytotoxicity in KB/V-1 cells, it appears that the likely demethylated metabolites of ARC-111, i.e., where NH2 or NHCH3 replaces the N(CH3)2 at the 2-position of the 5-ethyl substituent, are substrates for MDR1. In contrast, no significant difference in cytotoxicity among these three cell lines was observed with other N-alkyl analogues, including NHC2H5, NHCH(CH 3)2, NHC(CH3)3, N(CH 3)2, N(CH2CH3)2, NCH 3(CH-(CH3)2), and either the pyrrolidinyl or the piperidinyl analogues. The 2-(piperazinyl) analogues were associated with diminished cytotoxicity in KB/V-1 cells, suggesting that the second basic amino substituent is associated with their recognition as substrates by MDR1. Comparative studies on the antitumor activity of ARC-111 and its N-demethylated derivatives (the NHCH3 and NH2 analogues) against SJ-BT45 medulloblastoma xenografts in seid mice revealed that the secondary amine metabolite is at least as active as ARC-111 in vivo, although the primary amine derivative was significantly less potent.

5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: Novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity

5H-Dibenzo[c,h]1,6-naphthyridine-6-ones can exhibit potent antitumor activity. The effect of varied substituents at the 5-position of 5H-8,9-dimethoxy-2,3-methylenedioxydibenzo[c,h]1,6-naphthyridine on relative cytotoxicity and topoisomerase I-targeting a

Substituted 4-benzylquinolines

The present invention relates to compounds of the formula: SPC1 Wherein R1 is alkyl, R2 and R3 are hydrogen, halogen, alkyl, alkoxy, hydroxy, or methylenedioxy, and R4 and R5 are hydrogen, halogen, alkyl, alkoxy, hydroxy, or methylenedioxy and pharmaceutically acceptable salts thereof. These compounds are useful as antianginal agents.